Immuno-PET imaging to assess target engagement: Experience from 89Zr-anti-HER3 mAb (GSK2849330) in patients with solid tumors
- C. Willemien Menke-van der Houven van Oordt
- , Adam McGeoch
- , Mats Bergstrom
- , Iain McSherry
- , Deborah A. Smith
- , Matthew Cleveland
- , Wasfi Al-Azzam
- , Liangfu Chen
- , Henk Verheul
- , Otto S. Hoekstra
- , Danielle J. Vugts
- , Immanuel Freedman
- , Marc Huisman
- , Chris Matheny
- , Guus van Dongen
- , Sean Zhang
- Division of Experimental Medicine and Immunotherapeutics, Cambridge, United Kingdom
- OMID Molecular Imaging Consultancy, Uppsala, Sweden
- Clinical Pharmacology, Uxbridge, United Kingdom
- Clin Pharm Advantage, Durham, United States
- Bioimaging, Stevenage, United Kingdom
- Biopharm Product Development and Supply, King of Prussia, United States
- Drug Metabolism and Pharmacokinetics, King of Prussia, United States
- Department of Medical Oncology, Amsterdam, Netherlands
- Department of Radiology and Nuclear Medicine, Amsterdam, Netherlands
- Freedman Patent, Harleysville, United States
- Oncology R and D, King of Prussia, United States
- Hengrui Therapeutics, Princeton, United States
Research output: Contribution to journal › Article › Academic › peer-review
43
Downloads
(Pure)